CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ: XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI), effective Monday, December 22, 2014.
The NASDAQ Biotechnology Index includes securities of NASDAQ-listed companies classified as biotechnology or pharmaceutical companies. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on a semi-annual basis. It is the basis for the iShares NASDAQ Biotechnology Index(SM) Fund. All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements among other criteria.
Hey, check out all the engineering jobs. Post your resume today!
